Tessera Therapeutics vs Genentech
Side-by-side comparison of AI visibility scores, market position, and capabilities
Tessera Therapeutics is developing Gene Writing technology to insert large therapeutic sequences directly into the genome without double-strand DNA breaks; raised $230M+ including a $100M Series B;
About
Tessera Therapeutics is a genomic medicine company founded in 2018 by Jacob Rubens, Brian Goodman, and colleagues at Flagship Pioneering (the life sciences venture creation firm behind Moderna) and headquartered in Cambridge, Massachusetts. The company is pioneering Gene Writing — a platform technology that uses mobile genetic elements (specifically RNA-guided integrases derived from retrotransposons) to write large DNA sequences directly into the human genome at targeted sites, without requiring double-strand DNA breaks. This approach is designed to overcome key limitations of first-generation gene editing technologies: CRISPR-Cas9 creates double-strand breaks that can introduce unintended mutations, and current gene editing tools are largely limited to small sequence corrections or knockouts rather than full gene insertions.
Roche subsidiary and founding biotech; invented the biologics industry with recombinant DNA. Blockbuster oncology franchise includes Herceptin, Avastin, Rituxan, and Tecentriq.
About
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching the modern biotechnology industry. Acquired by Roche in 2009 for $46.8 billion, Genentech continues to operate with significant R&D autonomy as the US hub for Roche's pharmaceutical innovation.\n\nThe company is best known for pioneering cancer biologics, developing Herceptin (trastuzumab) for HER2-positive breast cancer, Avastin (bevacizumab) for multiple cancers, Rituxan (rituximab) for lymphoma, and Tecentriq (atezolizumab) for PD-L1 immunotherapy. Its discovery engine spans oncology, neuroscience, ophthalmology, and immunology with a robust early-stage pipeline leveraging AI-assisted target identification.\n\nGenentech generates tens of billions in annual revenue through Roche's Pharmaceuticals Division and remains one of the most productive biotech research sites in the world, consistently ranked among top employers in life sciences. The South San Francisco campus employs over 13,000 scientists, clinicians, and engineers, anchoring the Bay Area as a global biotech hub.
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.